Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
Not yet recruiting · NCT06178211 · Registry updated 2023-12-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Not yet recruiting | Phase 2 | 2023-12-20 | NCT06178211 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Chest Hospital | 116 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shanghai Chest Hospital | Shanghai | China | 56 |